- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06281106
TYK2 Inhibition in Paradoxical Psoriasis (TYPP)
Tyrosine Kinase 2 (TYK2) Inhibition in Paradoxical Psoriasis A Randomized, Double-blind, Placebo-controlled Multi-center Study Evaluating the Effect of Deucravacitinib on Severity of Psoriasis in Patients With Paradoxical Psoriasis
Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists.
This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Franziska Stuber, RN
- Phone Number: +41 21 3143427
- Email: franziska.stuber@chuv.ch
Study Locations
-
-
VD
-
Lausanne, VD, Switzerland, 1011
- Centre Hospitalier Universitaire Vaudois (Chuv)
-
Contact:
- Franziska Stuber, RN
- Phone Number: +41 21 3143427
- Email: franziska.stuber@chuv.ch
-
Principal Investigator:
- Curdin Conrad, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinical diagnosis of Paradoxical Psoriasis caused by anti-TNF treatment, with with Investigator Global Assessment ≥ 2 and Body Surface Area ≥ 2%
- Females who are of child-bearing potential should be practicing highly-effective contraception methods throughout the study and for 28 days after the last dose of study drug;
- Male subjects with a mechanical contraceptive method;
- be in good health
- be willing to have skin biopsies taken
Exclusion Criteria:
- Use of any other anti-psoriatic therapy. Certain washout periods of treatments needs to be respected
- Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline visit or oral anti-infectives within 14 days prior to the Baseline visit;
- A positive serology test for hepatitis B, hepatitis C, HIV;
- History of lymphoproliferative disease or of malignancy within the past 5 years.
- Chronic recurring bacterial infections or active tuberculosis;
- Positive pregnancy test at Screening and at the Baseline visit;
- Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;
- History of clinically significant alcohol or drug abuse in the last 12 months
- Known hypersensitivity to Deucravacitinib or any of its excipients
- Current severe progressive or uncontrolled disease
- Live vaccine within 12 weeks before Baseline Visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 'Deucravacitinib'
Deucravacitinib 6mg oral intake once daily for 4 weeks
|
Daily drug intake for 4 weeks.
|
Placebo Comparator: 'Placebo'
Matching Placebo oral intake once daily for 4 weeks
|
Daily drug intake for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Paradoxical Psoriasis Investigator Global Assessment
Time Frame: At Week 4
|
Percentage of patients attaining PxP IGA 0/1 and at least a reduction of 2 points from baseline
|
At Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Paradoxical Psoriasis Body Surface Area
Time Frame: At Week 4
|
Change of Paradoxical Psoriasis Body Surface Area ( PxP-BSA )
|
At Week 4
|
Paradoxical Psoriasis palmoplantar Psoriasis Area and Severity Index
Time Frame: at 4 Weeks
|
Change of Paradoxical Psoriasis palmoplantar Psoriasis Area and Severity Index (PxP PPPASI) Score in patients presenting paradoxical psoriasis of the hands of feet
|
at 4 Weeks
|
Paradoxical Psoriasis Scalp Investigator General Assessment
Time Frame: At Week 4
|
Change of Paradoxical Psoriasis Scalp Investigator General Assessment (PxP-scalp IGA) if paradoxical Psoriasis is affecting the Scalp
|
At Week 4
|
Psoriasis Area and Severity Index (PASI)
Time Frame: At Week 4 and at Week 16
|
Change of Psoriasis Area and Severity Index (PASI) in patients with pre-existing disease of Psoriasis
|
At Week 4 and at Week 16
|
American College of Rheumatology (ACR) Score
Time Frame: At Week 4 and Week 16
|
Percentage of patients with underlying disease of psoriasic arthritis, having an American College of Rheumatology (ACR) Score of 20%, 50% or 70% reduction in comparion with the Baseline assessment.
|
At Week 4 and Week 16
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nanostring
Time Frame: At Week 4
|
Normalization of inflammatory gene signature
|
At Week 4
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Curdin Conrad, Professor, CHUV centre hospitalier universitaire vaudois
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IM011-1118
- KOFAM 2023-01731 (Other Identifier: CER-VD)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Deucravacitinib
-
University of California, San FranciscoBristol-Myers SquibbNot yet recruiting
-
Centre Hospitalier Universitaire de NiceNot yet recruitingInflammatory Epidermal GenodermatosesFrance
-
Bristol-Myers SquibbRecruitingPlaque PsoriasisAustralia, Mexico, Canada, United Kingdom, France, Argentina, Japan, Poland, Spain, Korea, Republic of, Brazil, Germany, Romania
-
Handok Inc.CompletedBladder CancerKorea, Republic of
-
Bristol-Myers SquibbNot yet recruitingModerate-to-severe Plaque PsoriasisKorea, Republic of
-
Mayo ClinicBristol-Myers SquibbRecruiting
-
Brigham and Women's HospitalUniversity of PennsylvaniaRecruiting
-
Bristol-Myers SquibbCompletedCrohn Disease | Ulcerative ColitisRomania, Italy, United States, Australia, Canada, China, Germany, Hungary, Japan, Netherlands, Poland, Portugal, Russian Federation, Spain, Taiwan, United Kingdom
-
Janssen Research & Development, LLCRecruitingPlaque PsoriasisUnited States, Korea, Republic of, Germany, Taiwan, Poland, Brazil, Spain, Hungary, Australia, Canada, Romania